• Esco Medical Technologies has opened its new plant in Lithuania, which serves as a pivotal manufacturing hub in the EU, increasing production capabilities.
  • The facility is a €10.6 million investment, featuring an ergonomic design for optimal production flow. 
  • Our R&D and product management will also be co-located in the new plant to facilitate closer collaboration and accelerate innovation.
  • In addition to enhancing product aspects, the plant is expected to host training, seminars, and working sessions for service engineers, distributors, and potential clients.

LITHUANIA, 24 September 2024 – Esco Medical Technologies (“EMT”), a subsidiary of Esco Lifesciences Group, has launched operations at its new plant in Lithuania, located in the Kaunas Free Economic Zone. The two-story facility spans 7,900 sqm, significantly larger than the previous 2,900 sqm plant, allowing for expanded production capacity and speed. 

With R&D and product management located in the same facility as manufacturing, we aim to further drive innovation and strengthen our product development efforts.



The plant now houses around 80 employees and includes showrooms, meeting rooms, and seminar spaces. To promote employee health and well-being, it features large windows, air conditioning, showers, a spacious canteen, and will soon have a wellness room. The company also provides bus transportation and hosts a weekly sponsored lunch. Committed to sustainability, the plant has implemented bird protection initiatives, electric vehicle parking, and complies with A++ energy efficiency standards. 

“Our new EMT plant is now a key manufacturing and shared services hub within the EU, strengthening our market presence. The facility fosters innovation by supporting R&D, optimizing production, and establishing a training centre for service engineers and distributors. This demonstrates our commitment to customers and employees.

We are truly excited to see how this new chapter will drive Esco Lifesciences Group’s mission to enhance our impact in the EU and globally,” said XQ Lin, Chief Executive Officer of Esco Lifesciences Group.